8518981

2 known cases. View patent page →

Cases
2
Active
0
2 closed
Filed
2014–2015
Top venue
D Del Judge Gregory M Sleet
1 case

Untitled case

dismissed
Filed:
2014-12-01
Terminated:
2016-05-09

FDA Other Review document records a Hatch-Waxman suit asserting U.S. 8,518,981 and U.S. 8,598,218, referenced against NDA 207963 (Exela Pharma Sciences). The lawsuit was dismissed on May 9, 2016.

Helsinn Healthcare S.A. et al. v. Fresenius Kabi USA, LLC

voluntarily dismissed without prejudice
Docket:
1:15-cv-00918
Filed:
2015-10-13
Terminated:
2015-12-01

Helsinn and Roche asserted U.S. Patents 7,947,724; 8,518,981; 8,598,218; 9,066,980; and 9,125,905 against Fresenius Kabi in D. Del. based on Fresenius's Notice Letter regarding NDA No. 208109 for palonosetron HCl IV. Helsinn voluntarily dismissed the action without prejudice on 2015-12-01, and it was essentially refiled in New Jersey.